Molidustat, a promising drug to minimize HF risk following heart attack in diabetics - Medical Dialogues

It has been found in clinical trials that the drug may be potential treatment for a form of anaemia and could help reduce risk of developing heart failure in diabetes patients.In earlier research it has found that people with diabetes have lower levels of HIF in their heart cells.Oral Molidustat works by increasing levels of a protein called Hypoxia-Inducible Factor 1 (HIF).Molidustat is currently in phase III clinical trials for treating anaemia in chronic kidney disease.Previous study, however, has discovered that patients with diabetes had decreased amounts of HIF in their heart cells.Oral molidustat therapy restored the heart metabolic dysfunction induced by T2D in T2D rats, increasing glucose metabolism and mitochondrial activity while inhibiting fatty acid oxidation and lipid accumulation.Diabetic hearts have decreased angiogenesis, which is thought to be a crucial stage in the development of heart failure.The researchers concluded by pointing out that the encouraging findings imply that medicines that stabilize HIF might become a novel therapy to minimize the risk of heart failure following a heart attack in diabetics.